Novel Oncogenic Marker and Molecular Target for Treatment of Cancer

Legumain (LGMN) may serve as both a potential oncogenic marker and a molecular target for treatment of cancer especially for personalized medicine. Although recent findings have shed light on the functional roles and expression patterns of LGMN, further investigations are still warranted to elucidate the exact role and underlying mechanism of action for LGMN in cancer. LGMN, or asparaginyl endopeptidase, is a newly identified lysosomal cysteine protease. It was recently found to be over-expressed in tumor microenvironment , an enclosed environment that facilitates the interaction among the human solid tumors, tumor-associated endothelial and stromal cells, as well as in tumor-associated macrophages.

These non-malignant cells support the growth of the tumors, metastasis and the survival of tumors. One of the identified key biomarkers driving the complexity of tumor microenvironment is LGMN. LGMN is a robust acidic cysteine endopeptidase with remarkably restricted specificity for hydrolysis of asparaginyl bonds.

LGMN is well conserved, having been reportedly present in plants, invertebrate parasites, as well as in mammals. Mammalian LGMN processes the self and foreign antigens expressed by antigen presenting cells and proteolytically activates toll-like receptor, the innate immunity receptor.

Since LGMN has been implicated in tumor development and can potentially be developed into both diagnostic and therapeutic markers. This review aims to relate the recent findings on the biology of LGMN in cancers, to the therapeutic advancements in targeting LGMN in human cancers.

Recent discoveries have also demonstrated that targeting LGMN directly or utilizing LGMN as a prodrug activator are promising strategies for cancer management in the future. However, further research is necessary before such therapeutic strategies can be fully realized.

Source-Eurekalert